155 related articles for article (PubMed ID: 27997900)
1. A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes.
Ratanajarusiri T; Sriuranpong V; Sitthideatphaiboon P; Poovoravan N; Vinayanuwat C; Parinyanitikul N; Angspatt P; Thawinwisan W; Tanasanvimon S
Chemotherapy; 2017; 62(2):134-139. PubMed ID: 27997900
[TBL] [Abstract][Full Text] [Related]
2. Cross-sensitivity between taxanes in patients with breast cancer.
Sánchez-Muñoz A; Jiménez B; García-Tapiador A; Romero-García G; Medina L; Navarro V; González-Sánchez LA; Alba E
Clin Transl Oncol; 2011 Dec; 13(12):904-6. PubMed ID: 22126735
[TBL] [Abstract][Full Text] [Related]
3. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Feldweg AM; Lee CW; Matulonis UA; Castells M
Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
[TBL] [Abstract][Full Text] [Related]
4. Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?
Aoyama T; Takano M; Miyamoto M; Yoshikawa T; Soyama H; Kato K; Ishibashi H; Iwahashi H; Nakatsuka M; Yajima I; Shimizu Y; Aizawa Y; Suguchi Y; Moriiwa M; Goto T; Sasa H; Nagaoka I; Tsuda H; Furuya K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):65-69. PubMed ID: 28493032
[TBL] [Abstract][Full Text] [Related]
5. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
Lansinger OM; Biedermann S; He Z; Colevas AD
J Clin Oncol; 2021 Nov; 39(32):3583-3590. PubMed ID: 34357780
[TBL] [Abstract][Full Text] [Related]
6. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.
Picard M; Castells MC
Clin Rev Allergy Immunol; 2015 Oct; 49(2):177-91. PubMed ID: 24740483
[TBL] [Abstract][Full Text] [Related]
7. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
[TBL] [Abstract][Full Text] [Related]
8. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial assessing the utility of a test-dose program with taxanes.
Stanford BL; Shah SR; Ballard EE; Jumper CA; Rabinowitz I; Dowell JE; Hunt WC; Krieger JA
Curr Med Res Opin; 2005 Oct; 21(10):1611-6. PubMed ID: 16238901
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.
Bernstein BJ
Ann Pharmacother; 2000 Nov; 34(11):1332-5. PubMed ID: 11098349
[TBL] [Abstract][Full Text] [Related]
11. Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations.
Faqeer NA; Mashni O; Dawoud R; Rumman A; Hanoun E; Nazer L
J Clin Pharmacol; 2017 Feb; 57(2):275-279. PubMed ID: 27479828
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.
Picard M; Pur L; Caiado J; Giavina-Bianchi P; Galvão VR; Berlin ST; Campos SM; Matulonis UA; Castells MC
J Allergy Clin Immunol; 2016 Apr; 137(4):1154-1164.e12. PubMed ID: 26725998
[TBL] [Abstract][Full Text] [Related]
13. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program.
Dizon DS; Schwartz J; Rojan A; Miller J; Pires L; Disilvestro P; Gordinier ME; Moore R; Granai CO; Legare RD
Gynecol Oncol; 2006 Jan; 100(1):149-51. PubMed ID: 16197986
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?
Schwartz JR
J Oncol Pharm Pract; 2012 Jun; 18(2):250-6. PubMed ID: 21807762
[TBL] [Abstract][Full Text] [Related]
15. A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures.
Lynch DM; Menon S; Mazzola E; Costa J; Jabaley T
JCO Oncol Pract; 2023 Jun; 19(6):e942-e950. PubMed ID: 37058683
[TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity Reactions to Taxanes: A Multicenter Study for Outcomes and Safety of Rapid Drug Desensitization.
Bayrak Durmaz MS; Unutmaz DG; Demir M; Goksel O; Dursun AB; Bavbek S
Allergy Asthma Immunol Res; 2024 Mar; 16(2):142-153. PubMed ID: 38528382
[TBL] [Abstract][Full Text] [Related]
17. Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study).
Strobbe G; Gaboriau L; Abelé M; Villain A; Aelbrecht-Meurisse C; Carnot A; Le Deley MC; Léguillette C; Feutry F; Sakji I; Marliot G
Eur J Clin Pharmacol; 2023 Sep; 79(9):1229-1238. PubMed ID: 37438439
[TBL] [Abstract][Full Text] [Related]
18. Development of an enzyme-linked immunosorbent assay system to determine the presence of antibodies specific for taxane structures.
Muto S; Kouyama Y; Yokoyama Y; Okuno H; Ishii T; Masaka T; Matsuzawa Y; Kawashima T; Shirai K
Biol Pharm Bull; 2011; 34(4):562-6. PubMed ID: 21467646
[TBL] [Abstract][Full Text] [Related]
19. Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study.
Pagani M; Bavbek S; Dursun AB; Bonadonna P; Caralli M; Cernadas J; Cortellini G; Costantino MT; Gelincik A; Lucchini G; Castells M
J Allergy Clin Immunol Pract; 2019 Mar; 7(3):990-997. PubMed ID: 30292919
[TBL] [Abstract][Full Text] [Related]
20. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
Jao ME; Indorf AL; Segal EM; Miske A; Eaton KD; Marsolini T; Ghuman S
J Oncol Pharm Pract; 2024 Jan; 30(1):105-111. PubMed ID: 37021579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
